EXPLEOSOL
EXPLEOSOL
Each stock's 10,000-path forecast, rendered as light.
EXPLEOSOL (EXPLEOSOL) Stock Analysis & Case Study
Is EXPLEOSOL a good buy? The data-driven verdict.
EXPLEOSOL (EXPLEOSOL) trades at ₹825,on the numbers it screens attractive, a Downstox Snapshot Score of 74/100.
On the numbers, EXPLEOSOL (EXPLEOSOL) screens attractive, a Downstox Snapshot Score of 74/100, weighing inexpensive at 9.5× earnings, ROE of 19.2%, a 21% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
EXPLEOSOL fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
Is EXPLEOSOL overvalued? EXPLEOSOL P/E vs its sector
EXPLEOSOL's P/E of 9.5× sits below the sector peer median of 14.7×, so on earnings it screens cheaper than peers, while its 6.06% dividend yield is above the peer median of 1.67%.
EXPLEOSOL share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 2.0y of EXPLEOSOL history (-23%/yr drift, 37%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| EXPLEOSOL 2027 | ₹381 | ₹599 | ₹963 | -26% |
| EXPLEOSOL 2028 | ₹230 | ₹448 | ₹866 | -45% |
| EXPLEOSOL 2029 | ₹144 | ₹329 | ₹753 | -59% |
| EXPLEOSOL 2030 | ₹95 | ₹243 | ₹623 | -70% |
| EXPLEOSOL 2031 | ₹64 | ₹181 | ₹523 | -78% |
Median (P50) is the central estimate; the P10–P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability EXPLEOSOL goes up, or doubles?
The bull case for EXPLEOSOL
- Trades at just 9.5× earnings, below the ~22× long-run Nifty average, so the valuation leaves room rather than pricing in perfection.
- High return on equity (19.2%), the business compounds shareholder capital efficiently, the hallmark of a quality franchise.
- Strong ROCE (24.8%) shows the core business earns well above its cost of capital.
- Pays a 6.1% dividend yield, so you're partly paid to wait.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹753.
The bear case & risks
- The probability model is cautious 12 months out, only a 21% chance of finishing above today's price.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹144.
EXPLEOSOL volatility & expected range, how bumpy is the ride?
Over the last 2.0 years EXPLEOSOL compounded at -23%/year with annualized volatility of 37%. That volatility implies a 1-year 80% range of ₹381–₹963, the honest backbone behind any single price target.
EXPLEOSOL price forecast, the full 60-month probability fan
EXPLEOSOL price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds EXPLEOSOL hits common targets within the simulated horizon?
Full multi-horizon detail on the EXPLEOSOL price target & forecast page.
EXPLEOSOL Piotroski F-Score: 4/9, how financially strong is it?
The Piotroski F-Score grades financial strength on nine profitability, leverage and efficiency checks. EXPLEOSOL scores 4/9,mixed financial health.
EXPLEOSOL MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy EXPLEOSOL with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Zerodha | 50.0% | 2.0× |
| DhanCHEAPEST | 40.0% | 2.5× |
Compare every broker on the EXPLEOSOL MTF page.
EXPLEOSOL vs peers,sector comparison
About EXPLEOSOL: sector, index & market-cap context
EXPLEOSOL (EXPLEOSOL) is a small-cap NSE-listed company, and a constituent of the Nifty 500 index group, with a market capitalisation of ₹1,280 Cr. See more Nifty 500 stocks.
How the EXPLEOSOL Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of EXPLEOSOL's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
EXPLEOSOL analysis, FAQs
Is EXPLEOSOL (EXPLEOSOL) a good buy?
On the numbers, EXPLEOSOL (EXPLEOSOL) screens attractive, a Downstox Snapshot Score of 74/100, weighing inexpensive at 9.5× earnings, ROE of 19.2%, a 21% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is EXPLEOSOL overvalued or undervalued?
EXPLEOSOL trades at 9.5× earnings versus a peer median of 14.7×, so it screens cheaper than its sector peers.
What is the EXPLEOSOL share price target for 2031?
EXPLEOSOL's probability-weighted 2031 median target is ₹181, with an 80% range of ₹64–₹523 (10,000-path Monte-Carlo).
What is the probability EXPLEOSOL doubles in 5 years?
The modelled probability of EXPLEOSOL reaching ₹1,621 (2×) within 5 years is 0%.
What is the bull case for EXPLEOSOL?
Trades at just 9.5× earnings, below the ~22× long-run Nifty average, so the valuation leaves room rather than pricing in perfection. High return on equity (19.2%), the business compounds shareholder capital efficiently, the hallmark of a quality franchise. Strong ROCE (24.8%) shows the core business earns well above its cost of capital.
What are the risks in EXPLEOSOL?
The probability model is cautious 12 months out, only a 21% chance of finishing above today's price.